This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For 2022, pharmacy benefits managers (PBMs) and insurers expanded their dominance over specialty dispensing, though both hospitals and physician practices are growing their share of the market. The top three PBM-owned specialty pharmacies accounted for nearly two-thirds of prescription revenues from pharmacy-dispensed specialty drugs.
In upcoming articles, I’ll delve into chain and independentpharmacies’ participation in the major 2024 preferred networks. The 2024 data provide early evidence of a shrinking PDP market. I also update our analysis of the prevalence of preferred networks in three different types of MA-PD plans.
Plans from Aetna, Humana, WellCare, and UnitedHealthcare will not have any independentpharmacies participating via PSAOs as preferred pharmacies. Smaller pharmacies' ability to navigate away provides more bad news for stand-alone Part D market—and another unexpected consequence of the Inflation Reduction Act of 2022.
Among these, pharmacy benefit managers (PBMs) play a crucial role, handling reimbursements and negotiations with drug manufacturers and pharmacies. Three major PBM players – CVS Caremark, Express Scripts, and OptumRx – collectively command a significant 79% market share , orchestrating much of the industry’s dynamics.
For background, see Express Scripts + Prime Therapeutics: Our Four Takeaways From This Market Changing Deal. Payer-owned specialty pharmacies—via white, brown, and clear bagging—are trying to displace buy-and-bill distribution channels for provider-administered specialty drugs. The battle for specialty drug margin rages on.
Plans from Humana, WellCare, and UnitedHealthcare will again not have any independentpharmacies participating via PSAOs as preferred pharmacies. Thanks to the Inflation Reduction Act (IRA), the PDP market is vanishing. Looks like the presence of smaller pharmacies in preferred networks will not be far behind.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content